6. Ilumya

India's Sun Pharma
(Sun Pharma)

Active ingredient: tildrakizumab-asmn 
Disease: psoriasis 
Peak sales estimate: n/a
Approved: Mar. 21 
Company: Sun Pharma 

The scoop: For Sun, the approval of Ilumya was a milestone in its pivot toward specialty pharma after several years as an established generics player. But unfortunately for the Indian pharma, the green light didn’t come fast enough to beat out rival Tremfya from well-established psoriasis player Johnson & Johnson. While Ilumya, picked up from Merck in an $80 million licensing deal, might not have locked up the first-to-market advantage, though, it does have a dosing advantage over Tremfya. It requires doses just every 12 weeks after two initial treatments, compared with Tremfya’s every-8-weeks schedule. — Carly Helfand

6. Ilumya

Suggested Articles

Biotech leaders criticized the dismissals of Chinese scientists from U.S. universities in a letter with more than 150 signatures.

In this week's EuroBiotech Report, Merck allies with Themis on vaccine R&D, Juvenescence raises $100 million and GSK files for anemia approval. 

In our EuroBiotech roundup this week, Scancell withdraws IND, Oxurion’s eye drug fails phase 2a and Abivax starts ulcerative colitis trial.